You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

AFAtinib

( a-FA-ti-nib )
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Other Name(s): Giotrif® (Boehringer Ingelheim)
Appearance: tablet in various strengths and colours

You might also be interested in